Stock Price & Analysis

Based on the recent data and news, here's a comprehensive analysis of GSK stock:

Technical Analysis

The stock is showing bullish momentum with an upward trend, currently trading at $41.48. Key technical indicators:

• RSI(14) at 58.60 indicates moderate bullish momentum without being overbought
• MACD is positive with a reading of 0.63, suggesting continued upward momentum
• Stock is trading above both 20-day ($35.93) and 60-day ($34.60) moving averages

Fundamental Strength

Recent Q4 2024 results and outlook:

• Revenue reached $10.40 billion, beating analyst estimates of $9.58 billion
• Core EPS of $0.59, exceeding consensus of $0.43
• Announced $2.5 billion share buyback program over next 18 months
• Raised 2031 sales forecast to over £40 billion (previously £38 billion)

Growth Outlook

Management guidance for 2025:

• Revenue growth: 3-5%
• Core operating profit growth: 6-8%
• Core EPS growth: 6-8%
• Specialty Medicines expected to grow low double-digits
• Vaccine sales projected to decline low single-digits

Risk Factors

• High dividend payout ratio of 97% of earnings
• Earnings per share declined 12% annually over past five years
• Vaccine sales declined 14% in Q4 2024
• Competitive pressures in key markets

Buy/Sell Recommendation

SELL recommendation based on:

1. Current price ($41.48) is trading near resistance levels
2. High dividend payout ratio raises sustainability concerns
3. Historical earnings decline trend
4. Vaccine segment weakness could impact near-term growth
5. Stock has rallied significantly since Q4 results (+6.2%), suggesting much of the positive news is priced in

Price Targets

• Support level: $35.74 (Fibonacci S1)
• Resistance level: $37.03 (Fibonacci R1)
• JPMorgan price target: 1,500 GBp (maintains Underweight rating)

Based on the provided data and recent news, I'll analyze GSK's price outlook for 2025:

Price Analysis and Recent Performance

GSK has shown strong momentum recently, with the stock jumping significantly after its Q4 2024 earnings report. The company announced several positive developments:

• A $2.5 billion share buyback program over the next 18 months
• Raised long-term sales forecast to over £40 billion ($50 billion) by 2031
• Expected 2025 revenue growth of 3-5%
• Core earnings per share growth of 6-8% for 2025

Fundamental Drivers

The company's growth outlook is supported by:

• Accelerating momentum in specialty medicines portfolio
• Strong pipeline progress in key therapeutic areas including Respiratory, Immunology, Oncology and HIV
• Continued strength in HIV franchise with market-leading products
• Strategic focus on R&D investment in promising new long-acting medicines

2025 Price Prediction

Based on the company's guidance and current momentum, GSK stock is expected to reach $41-43 by end of 2025, representing a potential upside of 10-16% from current levels. This projection is supported by the company's strong fundamentals, strategic initiatives, and positive earnings growth trajectory.

The S1 support level for GSK Stock is $35.78 ,The R1 resistant level for GSK Stock is $37.98.

As of the end of day on 2025-02-26, the price of GSK Stock was $37.97.

The target price for GSK Stock according to analyst rating is 35.98, with the highest price target at 45.00 and the lowest at 17.91. Analysts have a Hold rating on GSK Stock overall.

The market cap of GSK is $159.0B.

Based on the comprehensive financial data and recent market updates, GSK appears fairly valued at current levels. The company's P/E ratio of 12.44x for FY2023 is below industry averages, suggesting reasonable valuation. Recent financial performance shows solid revenue growth with Q4 2024 sales reaching $10.40 billion, up 4% at constant currency. The company has announced a significant £2 billion share buyback program and raised its long-term sales forecast to over £40 billion by 2031, demonstrating management's confidence in future growth. However, dividend coverage concerns exist with a 97% payout ratio, though cash flow coverage remains adequate at 66%. The stock's technical indicators show neutral to slightly bullish momentum with RSI at 58.60 and positive MACD readings.

GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.

Based on the provided data and references, here's a comprehensive analysis for GSK's stock price prediction for 2030:

Price Target Analysis for 2030

GSK's stock is projected to reach approximately $45-47 by 2030, driven by three key factors:

1. Strong Pipeline Growth: GSK has raised its long-term sales forecast to over £40 billion ($50 billion) by 2031, up from previous guidance of £38 billion, reflecting confidence in late-stage pipeline progress. This represents a significant growth opportunity from current levels.

2. Strategic Focus: The company is increasing R&D investment in promising new long-acting and specialty medicines across Respiratory, Immunology & Inflammation, Oncology and HIV segments, which should drive sustainable growth through 2030.

3. Market Leadership: GSK is positioned to capture significant market share in key therapeutic areas, including the multiple myeloma market which is projected to reach $33 billion by 2030.

GSK has a total of 70212 employees.